HUTCHMED sets March 5 date for 2025 results

HUTCHMED (China) Limited has scheduled the release of its 2025 final results for March 5, 2026.

Accepted by SEC EDGAR 02/06/2026 - 06:06 AM EST

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

HUTCHMED (China) Limited has scheduled the release of its 2025 final results for March 5, 2026. The announcement will be made at 6:00 am EST, 11:00 am GMT and 7:00 pm HKT, giving investors in major markets simultaneous access.

Management will host two webcast presentations for analysts and investors to review the results and take questions. An English webcast is set for 8:00 am EST on March 5, 2026, and a Putonghua webcast for the Hong Kong and mainland China audience will follow on March 6, 2026. Live and replay access will be available via the company’s website.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will HUTCHMED (HCM) announce its 2025 final results?

HUTCHMED will announce its 2025 final results on Thursday, March 5, 2026. The release is scheduled for 6:00 am EST, which corresponds to 11:00 am GMT and 7:00 pm Hong Kong Time, allowing broad global investor access to the information simultaneously.

What investor webcasts is HUTCHMED (HCM) hosting for the 2025 results?

HUTCHMED will host two investor webcasts to discuss its 2025 final results. The English webcast is on March 5, 2026 at 8:00 am EST, while the Putonghua webcast is on March 6, 2026 at 8:30 am HKT, each followed by Q&A sessions.

How can investors access HUTCHMED (HCM) 2025 results webcasts and replays?

Investors can access HUTCHMED’s 2025 results webcasts live via the company website at www.hutch-med.com/event/. The presentation slides will be available shortly before each webcast, and replay recordings will be posted on the same site shortly after the events conclude.

In which languages will HUTCHMED (HCM) present its 2025 final results?

HUTCHMED will present its 2025 final results in both English and Putonghua. The English webcast targets global investors, while the Putonghua session focuses on Greater China audiences, offering language-appropriate presentations and Q&A opportunities for each investor group.

What type of company is HUTCHMED (HCM) according to this disclosure?

HUTCHMED is described as an innovative, commercial-stage biopharmaceutical company. It focuses on discovering, developing, and commercializing targeted therapies and immunotherapies for cancer and immunological diseases, with three medicines already marketed in China and one approved in major global markets.

Where is HUTCHMED (HCM) primarily based and listed?

HUTCHMED’s principal executive offices are in Hong Kong, and the company highlights its presence in Hong Kong, Shanghai and Florham Park, New Jersey. It is listed on Nasdaq and the Hong Kong Stock Exchange, reflecting both U.S. and Hong Kong capital market access.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

For the Month of February 2026

Commission File Number: 001-37710

HUTCHMED (CHINA) LIMITED

(Translation of registrant’s name into English)

48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⌧ Form 40-F ◻

HUTCHMED (CHINA) LIMITED

Form 6-K

EXHIBIT INDEX


Exhibit No.		Description

Exhibit 99.1		Announcement relating to notice of announcement of 2025 final results

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	HUTCHMED (CHINA) LIMITED


	By:	/s/ Johnny Cheng
	Name:	Johnny Cheng
	Title:	Chief Financial Officer

Date: February 6, 2026

Exhibit 99.1

HUTCHMED to Announce 2025 Final Results

Hong Kong, Shanghai & Florham Park, NJ — Friday, February 6, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2025 on Thursday, March 5, 2026 at 6:00 am Eastern Standard Time (EST) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong Time (HKT).

HUTCHMED management will host two webcast presentations for analysts and investors to discuss the final results, followed by Q&A sessions. The English webcast will be held on Thursday, March 5, 2026, at 8:00 am EST (1:00 pm GMT / 9:00 pm HKT). The Chinese (Putonghua) webcast will be held at 8:30 am HKT / 12:30 am GMT on Friday, March 6, 2026 (7:30 pm EST on Thursday, March 5, 2026).

Both webcasts will be available live via the website of the Company at www.hutch-med.com/event/. The presentation will be available to download shortly before the webcast begins. A replay will also be available on the website shortly after the event.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

CONTACTS


Investor Enquiries	+852 2121 8200 / ir@hutch-med.com

Media Enquiries
FTI Consulting –	+44 20 3727 1030 / HUTCHMED@fticonsulting.com
Ben Atwell / Tim Stamper	+44 7771 913 902 (Mobile) / +44 7421 898 348 (Mobile)
Brunswick – Zhou Yi	+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com

Panmure Liberum	Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden	+44 20 7886 2500

Cavendish	Joint Broker
Geoff Nash / Nigel Birks	+44 20 7220 0500

Deutsche Numis	Joint Broker
Freddie Barnfield / Jeffrey Wong / Duncan Monteith	+44 20 7260 1000

Source: View Original Filing on SEC EDGAR